1.
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
by Imperial, Marjorie Z
Nature medicine, 2018-11, Vol.24 (11), p.1708-1715
2.
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations
by Mayhew, David
Thorax, 2018-05, Vol.73 (5), p.422-430
3.
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
by Dorman, Susan E
The Lancet infectious diseases, 2018-01, Vol.18 (1), p.76-84
4.
Viruses and bacteria in sputum samples of children with community-acquired pneumonia
by Honkinen, M
Clinical microbiology and infection, 2012-03, Vol.18 (3), p.300-307
5.
Asthma-associated differences in microbial composition of induced sputum
by Marri, Pradeep Reddy, PhD
Journal of allergy and clinical immunology, 2012, Vol.131 (2), p.346-352.e3
6.
Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers
by Einarsson, G G
Thorax, 2016-09, Vol.71 (9), p.795-803
7.
A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD
by Wilkinson, Tom M A
Thorax, 2017-10, Vol.72 (10), p.919-927
8.
Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study
by Nicol, Mark P, Prof
The Lancet infectious diseases, 2011, Vol.11 (11), p.819-824
9.
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study
by Bates, Matthew, PhD
The Lancet infectious diseases, 2013, Vol.13 (1), p.36-42
10.
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-n...
by Suzuki, Motoi, MD
The Lancet infectious diseases, 2017, Vol.17 (3), p.313-321
11.
Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data
by Wang, Lixia, MS
The Lancet (British edition), 2014, Vol.383 (9934), p.2057-2064
12.
Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients
by Alanio, A
Clinical microbiology and infection, 2011-10, Vol.17 (10), p.1531-1537
13.
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
by Serisier, David J
Thorax, 2013-09, Vol.68 (9), p.812-817
14.
Sputum microbiota in severe asthma patients: Relationship to eosinophilic inflammation
by Li, Naijian
Respiratory medicine, 2017-10, Vol.131, p.192-198
15.
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial
by Theron, Grant, PhD
The Lancet (British edition), 2014, Vol.383 (9915), p.424-435
16.
Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study
by Wang, Zhang
Thorax, 2018-04, Vol.73 (4), p.331-338
17.
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
by Lawn, Stephen D, FRCP
The Lancet infectious diseases, 2013, Vol.13 (4), p.349-361
18.
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
by Diacon, Andreas H, Prof
The Lancet (British edition), 2012, Vol.380 (9846), p.986-993
19.
Effectiveness of bacteriophages in the sputum of cystic fibrosis patients
by Saussereau, E
Clinical microbiology and infection, 2014-12, Vol.20 (12), p.O983-O990
20.
Chronic obstructive pulmonary disease
by Decramer, Marc, Prof
The Lancet (British edition), 2012, Vol.379 (9823), p.1341-1351
